ABSTRACT
Objectives While the COVID-19 pandemic has had considerable global impact, recorded mortality in sub-Saharan Africa has been relatively low. Ensuring the public health response creates overall benefit is therefore critical. However, the highly age-dependent nature of COVID-19 mortality makes comparisons of disease burden challenging unless considered in terms of metrics that incorporate life years lost and time lived in adverse health. We therefore assessed the relative disease burdens of COVID-19 and the three major epidemic-causing pathogens; malaria, tuberculosis and HIV/AIDS, in sub-Saharan Africa.
Design We compared estimates of 2020 disease burdens in sub-Saharan African populations in terms of mortality and Disability-Adjusted Life Years lost (DALYs) for COVID-19, malaria, tuberculosis and HIV/AIDS, applying known age-related mortality to UN estimates of sub-Saharan population age structure. We further compared exacerbations of these diseases predicted to occur through the COVID-19 public health response. Data was derived from public sources, predicted disease exacerbations from those published by international agencies.
Main outcome measures Mortality and DALYs lost
Results For sub-Saharan African populations north of South Africa, recorded COVID-19 DALYs lost in 2020 was 2.0%, 1.2% and 1.3% of those estimated for tuberculosis, HIV/AIDS and malaria respectively. The predicted exacerbations alone of each of these comparator diseases were greater than the estimated COVID-19 burden. Including South Africa and Lesotho, COVID-19 DALYs lost were ≤6% of each of these predicted disease burdens and dominated by them in all age groups below 70 years.
Conclusions The analysis here suggests a relatively low impact from COVID-19. While all four epidemics continue, concentration on COVID-19 runs a high risk of increasing the overall health burden, further increasing global inequities in health and life expectancy, and needs to be guided by clear economic evaluation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding source: None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A. Public data only used.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Transparency statement The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that there are no discrepancies from the study as originally planned.
Data Availability
All data is in the public domain, and calculations are freely available from the authors.
List of abbreviations
- Africa CDC
- Africa Centres for Disease Control and Prevention
- AIDS
- Acquired Immune Deficiency Syndrome
- DALYs
- Disability-Adjusted Life Years
- HIV
- Human Immunodeficiency Virus
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Corona Virus 2
- WHO
- World Health Organization
